Novartis’ Kisqali has become the first drug in the CDK 4/6 inhibitor class to improve overall survival in metastatic breast cancer. The results of the MONALEESA-7 trial – reported
Exclusive live coverage from day three of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, pro
Epizyme has filed for accelerated FDA approval of tazemetostat for advanced epithelioid sarcoma (ES), a rare form of cancer with no approved drugs in the US.
Exclusive live coverage from day two of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, produ
Exclusive live coverage from day one of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, produ